Tomahawk, WI 08/12/2014 (Basicsmedia) – The ongoing Ebola crisis has been the longest and largest, flipping the script on the disease containment seen by the U.S and Spain flowing some of their infected nationals from West Africa. The contagious disease has aroused a number of ethical issues on the fact that drugs developed by pharmaceutical companies have only been used on Americans and a Spaniard without any African being given the medication. Companies like Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), Sarepta Therapeutics Inc. (NASDAQ:SRPT) GlaxoSmithKline plc (ADR) (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) are reported to be developing drugs for Ebola that have so far been tested on animals.

No cure or vaccine has been devised to counter the disease with the drugs being discussed in the biotech industry being in early stages of development according to CNBC’s Meg Tirrell.

“[..]They are all really-really in early stage I mean these things have either, just entered human trials, or I believe have only been tested in animals before, but we are looking at companies like Tekmira, Sarepta and Merck Biopharmaceuticals, ” said Tirrell.

An ongoing debate is already raging on who should get the drugs, currently being developed by the likes of Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), Sarepta and Johnson and Johnson as they are in the initial stages of development where supply is limited. The World Health Organization has already weighed into the discussion to dispense on how the drugs will be made available to the infected patients. The biggest challenge at the moment for the likes of Tekmira Sarepta and Johnson & Johnson (NYSE:JNJ) is the market size for the Ebola drugs that they are developing; a viable option in this case will be developing a vaccine that will attract mass sales.

Questions have already been raised’ on the effectiveness of the drugs being developed and being administered on patients, considering they have never before been used’ on humans. Long-term side effects if the drugs turnout to be successful also continues to be another biting issue.

“[…] that raises a lot of questions about who should get these drugs, and they are still so early in testing, and they are in such a limited supply of them. So the World Health Organization has actually convened a meeting of medical ethicists to discuss this question to try and figure out how do you dispense this medicine and to whom, how do you get consent for them, how do you test them and make sure they actually work,” said Tirrell.

 Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) stock continues to soar in the market as FDA allowed limited use of its Ebola drug with Glaxo and Johnson & Johnson (NYSE:JNJ) reported to be working on their Ebola drugs.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.